Targeted NGS confirms DLCN score cutoff for prioritising monogenic FH testing in CAD patients
Investigators evaluated the diagnostic yield of targeted next-generation sequencing for monogenic familial hypercholesterolaemia in 95 Uzbek patients with coronary artery disease. The study reports pathogenic or likely pathogenic variants in 18.9% of patients phenotypically classified as heterozygous FH, with the highest confirmation rate (46.7%) in those meeting the Dutch Lipid Clinic Network definite threshold of greater than 8 points, yielding 70.0% sensitivity and 90.2% specificity. These results support using the DLCN score greater than 8 as a practical triage threshold to prioritise genetic testing in regional laboratories, while noting that monogenic FH can still occur in patients with probable or possible scores.
The original study
Genetic yield of next-generation sequencing for detecting monogenic familial hypercholesterolemia in uzbek patients with coronary artery disease.
- Authors
- Alieva RB, Shek AB, Bahachova AV, Fozilov KG, Abdullaeva GJ, Abdullaev AA, et al.
- Journal
- PloS one
- Type
- Journal Article
- PMID
- 42424361
Original abstract
BACKGROUND: Familial hypercholesterolaemia (FH) is an inherited disorder with markedly elevated LDL-C and increased risk of premature atherosclerotic cardiovascular disease, most often caused by pathogenic variants in LDLR and less frequently APOB/PCSK9 (or recessive LDLRAP1). FH is commonly assessed using the Dutch Lipid Clinic Network (DLCN) score (definite >8, probable 6-8, possible 3-5). In Uzbekistan, genetic evidence for FH remains limited and largely based on candidate-variant studies, and the diagnostic yield of NGS for monogenic FH in CAD patients is not well defined. AIM: For the first time in Uzbekistan and Central Asia, to investigate FH-associated monogenic variants using next-generation sequencing (NGS) and to assess the validity of the DLCN criteria against genetic testing as the diagnostic reference standard in Uzbek patients with CAD and suspected FH. METHODS: This study included 95 patients with coronary artery disease (CAD) who underwent targeted NGS of LDLR, APOB, PCSK9, and LDLRAP1. The suspected/phenotypic FH group comprised 56 patients: 53 with DLCN-predicted heterozygous FH (HeFH)-possible (3-5 points, n = 22), probable (6-8 points, n = 16), and definite (>8 points, n = 15)-and 3 siblings from one family with a homozygous FH (HoFH) phenotype. The control group included 39 CAD patients with hypercholesterolemia without an FH diagnosis (DLCN 1-2 points). Only pathogenic/likely pathogenic (P/LP) variants were used for genetic confirmation of FH. RESULTS: Pathogenic/likely pathogenic variants were detected in 10/53 (18.9%) DLCN-predicted HeFH patients and in all three HoFH siblings. Genetic confirmation rates (PPV) were 46.7% (7/15) in definite HeFH, 12.5% (2/16) in probable HeFH, and 4.5% (1/22) in possible HeFH; no P/LP variants were detected in controls (0/39). Using a DLCN >8 threshold, sensitivity was 70.0% (7/10) and specificity was 90.2% (74/82) in the CAD cohort excluding the HoFH family. CONCLUSION: NGS confirmed the highest diagnostic yield in patients with DLCN >8, supporting its use as a practical threshold to prioritise genetic testing; however, monogenic FH may still be present in patients with probable or possible DLCN scores.